STRATEGIC NEWS WATCH — July 22, 2026
|
Arrowhead’s plozasiran cut triglycerides roughly 80% across two Phase 3 trials and reduced acute pancreatitis events 78%, an outcome RBC’s Luca Issi called a “best-case scenario”; separately, biotech leaders welcomed the FDA’s plan to hire thousands of staff after the loss of more than 3,000 employees, while pressing for assurances that politics will not interfere in drug reviews. Today’s top developments:
|
What to Watch
- Ivonescimab FDA decision (November 14, 2026) — This is the first U.S. filing for both ivonescimab and the PD-1xVEGF class; watch whether the updated survival analysis is treated as a major amendment, which would push the target action date out three months and test how much weight the agency gives a directional OS trend it explicitly asked to see cross significance.
- HARMONi-3 readout (expected 2026) — Final progression-free survival and interim overall survival data from Summit’s first-line NSCLC study land this year, following May’s interim miss on PFS significance; a clean result would reframe the class debate that the second-line data left unresolved.
- Plozasiran label expansion filing (by end of 2026) — Arrowhead plans to ask U.S. regulators before year-end to add severe hypertriglyceridemia to Redemplo’s label; quarterly dosing is the differentiator against Ionis’s once-monthly Tryngolza, which reached the indication first, but fuller datasets are needed before the head-to-head case holds.
- FDA staffing rebuild — The test is not the headcount but the timelines: whether hiring thousands of staff and revising clinical-trial standards restores measurable review predictability after the loss of more than 3,000 employees, including division heads.
- Cell therapy manufacturing consolidation — Repligen’s BioLife deal and the Cellares–Papillon automation partnership point the same direction: as commercial cell therapy volumes strain capacity, control of the manufacturing layer is becoming a strategic asset in its own right rather than an outsourced cost line.
This brief highlights the edition’s top stories. Read the full July 22, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.